NCT00523419

Chemotherapy for Patients With Osteosarcoma

Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition. * To assess how well treatment with pemetrexed works for patients with your type of cancer * To assess for any side effects that might be associated with pemetrexed. * To look at the characteristics and levels of certain of your genes and proteins to learn more about osteosarcoma and how pemetrexed works in your body.

Conditions

• Osteosarcoma

Interventions

Type	Name	Description
DRUG	Pemetrexed	500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.

Timeline

• Start date: 2007-09-01
• Primary completion: 2009-06-01
• Completion: 2010-06-01
• First posted: 2007-08-31
• Last updated: 2011-06-28
• Results posted: 2010-09-21

Locations

13 sites across 5 countries: France, Germany, Italy, Spain, United Kingdom